Avalo Therapeutics, Inc.
AVTX
Positions held
Your positionsAVTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $720.25M | Enterprise value | $320.22M | Trailing P/E | — | Forward P/E | -4.96 |
| PEG | — | Price / book | 1.58 | Beta | 0.70 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | -1548.5% |
| Profit margin | 0.0% | ROE | -36.3% | ROA | -18.5% | Debt / equity | 0.00 |
| Current ratio | 19.31 | Free cash flow | -$23.27M | Analyst recommendation | strong_buy | Mean target | $44.08 |
| 52w high | $24.27 | 52w low | $12.51 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.1M | $0.0M | $0.0M | — |
| Op margin | — | — | -33461.0% | — | — | — |
| Net income | -$36.4M | -$19.6M | -$13.7M | -$30.6M | -$20.8M | — |
| Gross margin | — | — | 100.0% | — | — | — |
| Gross profit | — | — | $0.1M | $0.0M | $0.0M | $0.0M |
| Operating income | -$31.5M | -$20.9M | -$19.7M | -$19.2M | -$19.3M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.1M | $0.4M | $1.9M | $18.1M | — |
| Op margin | -123601.7% | -9267.8% | -1218.5% | -207.4% | — |
| Net income | -$78.3M | -$35.1M | -$31.5M | -$41.7M | — |
| Gross margin | 100.0% | 183.0% | 33.3% | 81.0% | — |
| Gross profit | $0.1M | $0.8M | $0.6M | $14.6M | — |
| Operating income | -$72.9M | -$40.9M | -$23.4M | -$37.4M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-29 · Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
2026-09-23 · Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
2026-09-04 · Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
2026-09-03 · Avalo Therapeutics to Participate in Upcoming Investor Conferences
2026-08-19 · Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing
2026-08-11 · Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy?
2026-08-06 · Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
2026-07-22 · Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
2026-07-17 · Avalo Therapeutics Says Some Shareholders May Sell Up to 128,189 Shares
Price (daily)
Full chart · RSI · MACD · patterns